|
Press Releases |
|
|
|
Friday, March 29, 2024 |
|
乐普生物2023年收入快速增长,亏损大幅收窄,ADC进入收获期 |
more info >> |
|
樂普生物2023年收入快速增長,虧損大幅收窄,ADC進入收穫期 |
more info >> |
|
Friday, August 25, 2023 |
|
乐普生物公布2023年中期业绩 |
聚焦于肿瘤治疗领域的创新型生物制药公司──乐普生物科技股份有限公司(「乐普生物」或「公司」,股份代号:2157.HK),于今日公布2023年中期业绩。 more info >> |
|
樂普生物公佈2023年中期業績 |
聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」,股份代號:2157.HK),於今日公佈2023年中期業績。 more info >> |
|
Friday, March 17, 2023 |
|
乐普生物公布2022年度业绩 |
聚焦于肿瘤治疗领域的创新型生物制药公司──乐普生物科技股份有限公司(「乐普生物」或「公司」,股份代号:2157.HK),于今日公布2022年度业绩。 more info >> |
|
樂普生物公佈2022年度業績 |
聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」,股份代號:2157.HK),於今日公佈2022年度業績。 more info >> |
|
Thursday, February 23, 2023 |
|
乐普生物和康诺亚共同宣布与阿斯利康就CMG901达成全球独家授权协议 |
乐普生物科技股份有限公司 (HK:02157)和康诺亚生物医药科技有限公司(HK:02162)今日共同宣布与阿斯利康(AstraZeneca,LSE/STO/纳斯达克:AZN)就潜在世界首创Claudin 18.2抗体偶联药物CMG901达成全球独家授权协议。 more info >> |
|
樂普生物和康諾亞共同宣佈與阿斯利康就CMG901達成全球獨家授權協定 |
樂普生物科技股份有限公司 (HK:02157)和康諾亞生物醫藥科技有限公司(HK:02162)今日共同宣佈與阿斯利康(AstraZeneca,LSE/STO/納斯達克:AZN)就潛在世界首創Claudin 18.2抗體偶聯藥物CMG901達成全球獨家授權協定。 more info >> |
|
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901 |
On 23 February, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). more info >> |
|
Thursday, September 29, 2022 |
|
乐普生物PD-1单抗普佑恒(TM)获批新适应症,MRG003获CDE纳入突破性治疗药物名单 |
乐普生物科技股份有限公司 (「乐普生物」或「公司」,股份代号:2157.HK) 宣布,公司旗下首款创新型生物药抗PD-1抗体——普佑恒™(通用名:普特利单抗注射液)已获得国家药品监督管理局(NMPA)批准上市销售。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles
May 15, 2024 14:30 JST
|
|
|
Intermodal Terminal Company (ITC) Chooses Hexagon to Deliver Groundbreaking Australian Rail Terminal
May 15, 2024 12:32 HKT/SGT
|
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 11:19 JST
|
|
|
Honda、将来のSDV実現に向け、IBMと次世代半導体・ソフトウェア技術の長期共同研究開発に関する覚書を締結
May 15, 2024 10:00: JST
|
|
|
Five Tips to build Personalised Engagement with your Customers
May 15, 2024 09:05 HKT/SGT
|
|
|
Former Microsoft, IBM and Compaq Executive to Head APJ Expansion for GTDC
May 15, 2024 09:00 HKT/SGT
|
|
|
上海机电拟收购上海集优 利好催化构建双轮驱动发展格局
May 14, 2024 21:01 HKT/SGT
|
|
|
上海機電擬收購上海集優 利好催化構建雙輪驅動發展格局
May 14, 2024 20:59 HKT/SGT
|
|
|
SMEIC Proposal to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern
May 14, 2024 20:54 HKT/SGT
|
|
|
AsiaMedic partners with Sunway to establish new diagnostic imaging centre
May 14, 2024 18:00 HKT/SGT
|
|
|
雲頂新耀為創新藥物賦能,耐賦康(R)開啟中國腎病治療新時代
May 14, 2024 17:59 HKT/SGT
|
|
|
云顶新耀为创新药物赋能,耐赋康(R)开启中国肾病治疗新时代
May 14, 2024 17:59 HKT/SGT
|
|
|
InfoComm Asia 2024 "Asia's International Pro AV Exhibition" Returns to Thailand
May 14, 2024 16:30 HKT/SGT
|
|
|
3rd Annual Clean Power & New Energy 2024
May 14, 2024 16:03 HKT/SGT
|
|
|
Dubai FinTech Summit concludes with over 8,000 visitors from 118 countries
May 14, 2024 14:06 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|